Authors
Latest:
Dr Epstein-Peterson on the Use of CAR T-Cell Therapy in MCLZachary Epstein-Peterson, MD, discusses the use of CAR T-cell therapy in mantle cell lymphoma and highlights questions that remain to be answered within the treatment landscape.
Latest:
Dr D’Amico on Advancements in High-Risk Prostate Cancer Diagnosis and ManagementAnthony V. D'Amico, MD, PhD, on the advancements in high-risk prostate cancer diagnosis and management
Latest:
Dr Johnson the Accuracy of Genomic Testing in Black Women With ER+ Breast CancerNathalie McDowell Johnson, MD, FACS, discusses the accuracy of genomic testing in Black women with estrogen receptor-positive breast cancer.
Latest:
Demystifying the Role of Palliative Care in the Oncology ClinicDespite American Society of Clinical Oncology guidelines calling for introduction of palliative care early in the course of disease, these services remain underused.
Latest:
Taking Organoids From Bench to Bedside Through Endoscopy in Pancreatic Cancer: Ongoing ResearchIn this seventh episode of OncChats: Taking Organoids From Bench to Bedside Through Endoscopy in Pancreatic Cancer, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Richard Burkhart, MD, discuss ongoing research such as the PASS-01 trial (NCT04469556) in pancreatic cancer and ways to translate advances in the metastatic setting to the curative setting.
Latest:
Optimizing Care of Patients With Advanced Prostate Cancer: ConclusionSummarizes the main points and benefits of multidisciplinary prostate cancer care.
Latest:
Dr Garcia on the Future of the MELISA Trial in Ovarian CancerNúria Agustí Garcia, MD, discusses the mapping of sentinel lymph nodes in early-stage ovarian cancer.
Latest:
Dr. Kato on the Rationale For Investigating Dato-DXd Plus Durvalumab and Carboplatin in Advanced NSCLCTerufumi Kato, MD, Terufumi Kato, MD, Chief Physician, Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan, discusses the ongoing investigation of datopotamab deruxtecan in combination with durvalumab and carboplatin as a first-line treatment for patients with advanced metastatic non–small cell lung cancer.
Latest:
Dr Pagliaro on the Use of First-Line Avelumab Maintenance Therapy in Urothelial CarcinomaLance C. Pagliaro, MD, discusses the efficacy of first-line avelumab maintenance therapy, as seen in the phase 3 JAVELIN Bladder 100 trial in patients with advanced urothelial carcinoma.
Latest:
Dr. Pederson on the Importance of Ancestrally-Unbiased Polygenic Risk Assessment in Breast CancerHolly Pederson, MD, discusses the importance of ancestrally-unbiased polygenic risk assessment in patients with breast cancer.
Latest:
Dr. Mehta on the Rationale for Utilizing Parsaclisib in Relapsed or Refractory MCLAmitkumar Mehta, MD, discusses the rationale behind utilizing parsaclisib in relapsed or refractory mantle cell lymphoma as part of the phase 2 CITADEL-205 study.
Latest:
Experts Discuss the Management of Paronychia When Treating Patients with EGFR TKIsZosia Piotrowska, MD, Christine Lovly, MD, PhD, and Amanda Cass, PharmD, BCPS, BCOP, discuss the management of paronychia when treating patients with EGFR TKIs.
Latest:
Optimizing the Selection of Novel Therapy for Patients With Advanced NSCLCClosing out their panel on immunotherapy in non–small cell lung cancer, expert oncologists share key takeaways on the selection of novel therapy in this setting.
Latest:
The Podcast by Fellows for FellowsDaniel J. Hausrath, MD, discusses a collaborative effort to produce a podcast for fellows that reviews the fundamentals, core concepts, and important management approaches in the field, as determined by the latest evidence and expert opinion.
Latest:
Dr. DeCesaris on Classical vs Contemporary Indications for Radiation in Breast CancerCristina DeCesaris, MD, discusses classical indications for breast cancer radiation and how these methods are being contextualized in the contemporary treatment era.
Latest:
Dr. Greene on the Future of Personalized Therapy in Prostate CancerKirsten L. Greene, MD, MAS, FACS, discusses the future of personalized therapy in prostate cancer.
Latest:
Treatment Landscape Shifts Away From Chemotherapy Toward Targeted Approaches in ALLNovel approaches with highly active, minimally toxic agents are needed to improve upon traditional chemotherapy and possibly eliminate chemotherapy altogether in the treatment of patients with acute lymphoblastic leukemia.
Latest:
Student Loan Debt, Immigration Status Often Drive Career Decisions for FellowsInvestigators from Indiana University decided to study some of the factors influencing career plans for physicians, focusing on current fellows and recent graduates of the hematology and medical oncology specialty in the United States.
Latest:
Holistic and Multidisciplinary Approaches to Multiple Myeloma ManagementClosing out their program on multiple myeloma, expert panelists consider the role of holistic and multidisciplinary care when managing patients within the current paradigm.
Latest:
Dr Alfonso Piérola on Unmet Needs in Higher-Risk MDSAna Alfonso Piérola, MD, PhD, discusses unmet needs for patients with high-risk myelodysplastic syndrome.
Latest:
MRD and ctDNA Could Shift into Larger Role to Guide Treatment Decisions in Breast CancerPraveen Vikas, MBBS, discusses what is currently known regarding minimal residual disease testing in breast cancer, expanded on what still needs to be done to bring minimal residual disease and ctDNA testing to clinical practice, and highlighted the evolving treatment paradigm for patients with advanced hormone receptor-positive, HER2-negative breast cancer.
Latest:
Dr. Frigault on Toxicity Differences Among CAR T-Cell Products in Leukemias, LymphomasMatthew Frigault, MD, discusses differences in the toxicities experienced with CAR T-cell products used in the treatment of patients with leukemias and lymphomas.
Latest:
Dr Rodriguez on the Use of HER2-Directed Therapies in NSCLCEstelamari Rodriguez, MD, MPH, discusses adverse effects associated with HER2-directed antibody-drug conjugates in non–small cell lung cancer.
Latest:
Dr Beksac on OS Data From the OPTIMISMM Trial in Relapsed/Refractory Multiple MyelomaMeral Beksac, MD, discusses overall survival data from the phase 3 OPTIMISMM trial in relapsed/refractory multiple myeloma.
Latest:
Dr Yaeger on the Implications of Data With Second-Line Sotorasib Plus Panitumumab in mCRCRona Yaeger, MD, discusses the implications of data with second-line sotorasib plus panitumumab in KRAS G12C–mutated metastatic colorectal cancer.
Latest:
Dr McAndrew on the HER2CLIMB-02 Trial in HER2+ Breast CancerNicholas P. McAndrew, MD, MSCE, discusses the phase 3 HER2CLIMB-02 trial of tucatinib plus trastuzumab emtansine in HER2-positive early breast cancer.
Latest:
Future Directions for mCRC ManagementGerald Prager, MD; Chiara Cremolini, MD, PhD; and Tanios S. Bekaii-Saab, MD, review emerging strategies and the future treatment landscape for metastatic colorectal cancer.
Latest:
Fellows on Film: What Makes a Good Mentor for an Oncology Fellow?Michael L. Grossbard, MD, and Rabi Upadhyay, MD, Instructor, Department of Medicine at NYU Grossman School of Medicine, discuss the qualities that make someone a great mentor for an oncology fellow.
Latest:
Dr. Santa-Maria on Trastuzumab Deruxtecan in HER2-low TNBCCesar A. Santa-Maria, MD, discusses exploratory data seen with trastuzumab deruxtecan in patients with triple-negative breast cancer.
